Association between Cholesterol Level and Mortality in Dialysis Patients: Role of Inflammation and Malnutrition

JAMA

Volumn 291, Issue 4, 2004, Pages 451-459

  Liu, Yongmei ^a   Coresh, Josef ^a   Eustace, Joseph A ^a   Longenecker, J Craig ^a,b   Jaar, Bernard ^a   Fink, Nancy E ^a   Tracy, Russell P ^c   Powe, Neil R ^a   Klag, Michael J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KUWAIT UNIVERSITY   (Kuwait)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; INTERLEUKIN 6; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DEATH; DIALYSIS; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 1642540483     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.4.451     Document Type: Article

References (41)

1. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458-482.
2. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887-1893.
3. Coresh J, Longenecker JC, Miller ER III, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol. 1998;9(12 suppl):S24-S30.
4. National Kidney Foundation. K/DOQI Clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41(4 suppl 3): S22-S59.
5. Baigent C, Wheeler DC. Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure? Nephrol Dial Transplant. 2000;15:1118-1119.
6. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet. 2001;358:351-355.
7. Cullen P, Schulte H, Assmann G. The Munster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation. 1997;96:2128-2136.
8. Dyker AG, Weir CJ, Lees KR. Influence of cholesterol on survival after stroke: retrospective study. BMJ. 1997;314:1584-1588.
9. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8:216-224.
10. Behar S, Graff E, Reicher-Reiss H, Boyko V, Benderly M, Shotan A, et al. Low total cholesterol is associated with high total mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Study Group. Eur Heart J. 1997;18:52-59.
11. US Renal Data System. USRDS 1999 annual data report. Am J Kidney Dis. 1999;34(2 suppl 1):S87-S94.
12. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:297-304.
13. Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol. 2001;12:1549-1557.
14. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003;290:353-359.
15. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome. Nephrol Dial Transplant. 2002;17(suppl 11):28-31.
16. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998;32:107-114.
17. Sammalkorpi KT, Valtonen VV, Maury CP. Lipoproteins and acute phase response during acute infection: interrelationships between C-reactive protein and serum amyloid-A protein and lipoproteins. Ann Med. 1990;22:397-401.
18. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002;13:1918-1927.
19. Rocco MV, Yan G, Gassman J, Lewis JB, Ornt D, Weiss B, et al. Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems: the National Institutes of Health-funded Hemodialysis: Health Care Financing Administration. Am J Kidney Dis. 2002;39:146-153.
20. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127
21. Third National Health and Nutrition Examination Survey (NHANES III) [Centers for Disease Control and Prevention Web site] Available at: http://www.cdc.gov/nchs/about/major/nhanes/nh3data .htm. Accessed July 16, 2003.
22. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002;57:M326-M332.
23. Executive summary of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). JAMA. 2001;285:2486-2497.
24. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074-1078.
25. Nieto FJ, Coresh J. Adjusting survival curves for confounders: a review and a new method. Am J Epidemiol. 1996;143:1059-1068.
26. United States Renal Data System. USRDS 1999 Annual Data Report. Bethesda, Md: National Institutes of Health; 1999.
27. Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, et al. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int. 2003;63(suppl 84):117-120.
28. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int. 2002;61(suppl 80):103-108.
29. Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients: the HEMO Study Group. Kidney Int. 2000;58:346-352.
30. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 1992;52:4113-4116.
31. Attman PO, Alaupovic P, Tavella M, Knight-Gibson C. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant. 1996;11:63-69.
32. Lowrie EG. Acute-phase inflammatory processcontributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients. Am J Kidney Dis 1998;32(6 suppl 4):S105-S112.
33. Kaysen GA. Role of Inflammation and its treatment in ESRD patients. Blood Purif. 2002;20:70-80.
34. Harris T, Feldman JJ, Kleinman JC, Ettinger WH Jr, Makuc DM, Schatzkin AG. The low cholesterolmortality association in a national cohort. J Clin Epidemiol. 1992;45:595-601.
35. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial: Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992;152:1490-1500.
36. Salmond CE, Beaglehole R, Prior IA. Are low cholesterol values associated with excess mortality? BMJ. 1985;290:422-424.
37. Iribarren C, Reed DM, Burchfiel CM, Dwyer JH. Serum total cholesterol and mortality: confounding factors and risk modification in Japanese-American men. JAMA. 1995;273:1926-1932.
38. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA. 1987;257:2176-2180.
39. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
40. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
41. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.